Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Homocamptothecin Payloads with Enhanced Potency for Antibody-Drug Conjugates.

Created on 10 Sep 2026

Authors

Jiajun Xie, Yalong Li, Fengyuan Pan, Yifan Wang, Wei Lu, Bo Wang, Shulei Zhu, Juan Zhang

Published in

Journal of medicinal chemistry. Volume 69. Issue 17. Pages 20213-20229. Sep 10, 2026.

Abstract

Camptothecin derivatives, exemplified by DXd, are a dominant class of payloads for antibody-drug conjugates (ADCs). Herein, we describe the design and synthesis of H2, a novel homocamptothecin featuring a simplified hydroxybutyl structure that circumvents the complex assembly of the F-ring. H2 exhibits superior hydrolytic stability, while maintaining potent intrinsic cytotoxicity. In vitro, the H2-conjugated ADC candidates, Tras-L-H2 and Tras-TL-H2, demonstrated robust bystander killing effect and potent antiproliferative activity, similar to that observed with T-DXd. Importantly, these candidates exhibited noninferior antitumor efficacy to that of T-DXd in JIMT-1 xenograft model. These findings demonstrate the therapeutic utility of the seven-membered homocamptothecin scaffold and identify H2 as a promising candidate for next-generation ADC payloads.

PMID:
42720475
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement